These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 3018703

  • 1. Comparative structural requirements of thirty GRF analogs for interaction with GRF- and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas.
    Robberecht P, Waelbroeck M, Coy D, De Neef P, Camus JC, Christophe J.
    Peptides; 1986; 7 Suppl 1():53-9. PubMed ID: 3018703
    [Abstract] [Full Text] [Related]

  • 2. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist.
    Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J.
    Endocrinology; 1985 Jun; 116(6):2643-9. PubMed ID: 2859987
    [Abstract] [Full Text] [Related]

  • 3. Structural requirements for the activation of rat anterior pituitary adenylate cyclase by growth hormone-releasing factor (GRF): discovery of (N-Ac-Tyr1, D-Arg2)-GRF(1-29)-NH2 as a GRF antagonist on membranes.
    Robberecht P, Coy DH, Waelbroeck M, Heiman ML, de Neef P, Camus JC, Christophe J.
    Endocrinology; 1985 Nov; 117(5):1759-64. PubMed ID: 2994998
    [Abstract] [Full Text] [Related]

  • 4. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
    Robberecht P, Coy DH, De Neef P, Camus JC, Cauvin A, Waelbroeck M, Christophe J.
    Eur J Biochem; 1986 Aug 15; 159(1):45-9. PubMed ID: 3017717
    [Abstract] [Full Text] [Related]

  • 5. Study of species specificity in growth hormone-releasing factor (GRF) interaction with vasoactive intestinal peptide (VIP) receptors using GRF and intestinal VIP receptors from rat and human: evidence that Ac-Tyr1hGRF is a competitive VIP antagonist in the rat.
    Laburthe M, Couvineau A, Rouyer-Fessard C.
    Mol Pharmacol; 1986 Jan 15; 29(1):23-7. PubMed ID: 3003561
    [Abstract] [Full Text] [Related]

  • 6. Identification of receptor-binding pharmacophores of growth-hormone-releasing factor in rat adenopituitary.
    Lefrançois L, Gaudreau P.
    Neuroendocrinology; 1994 Apr 15; 59(4):363-70. PubMed ID: 8202217
    [Abstract] [Full Text] [Related]

  • 7. Vasoactive intestinal peptide receptor antagonists in rat seminal vesicle membranes.
    Rodríguez-Pena MS, Guijarro LG, Prieto JC.
    Eur J Pharmacol; 1991 Nov 13; 208(3):207-12. PubMed ID: 1663044
    [Abstract] [Full Text] [Related]

  • 8. Specific labelling of high-affinity vasoactive intestinal peptide receptors in rat liver membranes by a growth hormone-releasing factor analog.
    Robberecht P, Coy DH, De Neef P, Camus JC, Waelbroeck M, Christophe J.
    Neuroendocrinology; 1986 Nov 13; 44(1):108-11. PubMed ID: 3024053
    [Abstract] [Full Text] [Related]

  • 9. Vasoactive intestinal peptide receptors in pancreas and liver. Structure-function relationship.
    Christophe J, Svoboda M, Waelbroeck M, Winand J, Robberecht P.
    Ann N Y Acad Sci; 1988 Nov 13; 527():238-56. PubMed ID: 2839079
    [Abstract] [Full Text] [Related]

  • 10. Interaction of GRF with VIP receptors and stimulation of adenylate cyclase in rat and human intestinal epithelial membranes. Comparison with PHI and secretin.
    Laburthe M, Amiranoff B, Boige N, Rouyer-Fessard C, Tatemoto K, Moroder L.
    FEBS Lett; 1983 Aug 08; 159(1-2):89-92. PubMed ID: 6307754
    [Abstract] [Full Text] [Related]

  • 11. Characterization of VIP receptor-effector system antagonists in rat and mouse peritoneal macrophages.
    Pozo D, Montilla ML, Guerrero JM, Calvo JR.
    Eur J Pharmacol; 1997 Mar 05; 321(3):379-86. PubMed ID: 9085051
    [Abstract] [Full Text] [Related]

  • 12. Effector mechanisms of peptides of the VIP family.
    Christophe J, Svoboda M, Lambert M, Waelbroeck M, Winand J, Dehaye JP, Vandermeers-Piret MC, Vandermeers A, Robberecht P.
    Peptides; 1986 Mar 05; 7 Suppl 1():101-7. PubMed ID: 3018687
    [Abstract] [Full Text] [Related]

  • 13. Effects of HIS1 modifications on the ability of vasoactive intestinal peptide to stimulate adenylate cyclase from rat and human tissues.
    Robberecht P, Waelbroeck M, Camus JC, De Neef P, Coy D, Christophe J.
    Peptides; 1984 Mar 05; 5(5):877-81. PubMed ID: 6504721
    [Abstract] [Full Text] [Related]

  • 14. Receptor-mediated actions of growth hormone releasing factor on granulosa cell differentiation.
    Moretti C, Bagnato A, Solan N, Frajese G, Catt KJ.
    Endocrinology; 1990 Nov 05; 127(5):2117-26. PubMed ID: 2171907
    [Abstract] [Full Text] [Related]

  • 15. [D-Phe4]peptide histidine-isoleucinamide ([D-Phe4]PHI), a highly selective vasoactive-intestinal-peptide (VIP) agonist, discriminates VIP-preferring from secretin-preferring receptors in rat pancreatic membranes.
    Robberecht P, Coy DH, De Neef P, Camus JC, Cauvin A, Waelbroeck M, Christophe J.
    Eur J Biochem; 1987 Jun 01; 165(2):243-9. PubMed ID: 3036504
    [Abstract] [Full Text] [Related]

  • 16. Somatostatin inhibits growth hormone-releasing factor-stimulated adenylate cyclase activity in GH, cells.
    Reyl-Desmars F, Zeytin F.
    Biochem Biophys Res Commun; 1985 Mar 29; 127(3):986-91. PubMed ID: 2859018
    [Abstract] [Full Text] [Related]

  • 17. GRF is a highly potent activator of adenylate cyclase in the normal human, bovine and rat pituitary: interaction with somatostatin.
    Reyl-Desmars F, Baird A, Zeytin FN.
    Biochem Biophys Res Commun; 1985 Mar 29; 127(3):977-85. PubMed ID: 2859017
    [Abstract] [Full Text] [Related]

  • 18. Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro.
    Rekasi Z, Varga JL, Schally AV, Halmos G, Groot K, Czompoly T.
    Proc Natl Acad Sci U S A; 2000 Feb 01; 97(3):1218-23. PubMed ID: 10655511
    [Abstract] [Full Text] [Related]

  • 19. Binding of vasoactive intestinal peptide and its stimulation of adenylate cyclase through two classes of receptors in rat liver membranes. Effects of 12 secretin analogues and 2 secretin fragments.
    Waelbroeck M, Robberecht P, De Neef P, Chatelain P, Christophe J.
    Biochim Biophys Acta; 1981 Nov 18; 678(1):83-90. PubMed ID: 6272875
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological, molecular and functional characterization of vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptors in the rat pineal gland.
    Simonneaux V, Kienlen-Campard P, Loeffler JP, Basille M, Gonzalez BJ, Vaudry H, Robberecht P, Pévet P.
    Neuroscience; 1998 Aug 18; 85(3):887-96. PubMed ID: 9639281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.